Moleculin Biotech, Inc. (NASDAQ:MBRX) CEO Purchases $82,656.61 in Stock

Moleculin Biotech, Inc. (NASDAQ:MBRXGet Rating) CEO Walter V. Klemp acquired 85,213 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was purchased at an average price of $0.97 per share, for a total transaction of $82,656.61. Following the completion of the transaction, the chief executive officer now owns 317,648 shares in the company, valued at $308,118.56. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Moleculin Biotech Stock Performance

Moleculin Biotech stock opened at $1.05 on Monday. Moleculin Biotech, Inc. has a one year low of $0.82 and a one year high of $2.33. The business has a fifty day moving average of $1.06 and a two-hundred day moving average of $1.37. The company has a market cap of $30.06 million, a P/E ratio of -1.21 and a beta of 1.77.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MBRX. StockNews.com began coverage on shares of Moleculin Biotech in a research report on Friday. They issued a “sell” rating on the stock. Roth Capital reduced their target price on Moleculin Biotech from $29.00 to $16.00 in a report on Tuesday, August 16th. Finally, Oppenheimer reduced their target price on Moleculin Biotech from $14.00 to $5.00 in a report on Friday, November 11th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Walker Asset Management LLC acquired a new position in shares of Moleculin Biotech during the 2nd quarter worth $32,000. Renaissance Technologies LLC raised its stake in shares of Moleculin Biotech by 79.3% during the 1st quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock worth $107,000 after buying an additional 26,500 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Moleculin Biotech by 19.2% during the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after buying an additional 11,497 shares during the last quarter. Institutional investors and hedge funds own 10.48% of the company’s stock.

Moleculin Biotech Company Profile

(Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

See Also

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.